
  
    
      
        
        A_DT year_NN ago_RB ,_, I_PRP received_VBD an_DT E-_NNP mail_NN from_IN a_DT research_NN scientist_NN at_IN a_DT major_JJ pharmaceutical_JJ
        company_NN ._. The_DT scientist_NN had_VBD read_VBN my_PRP$ articles_NNS on_IN whistleblowers_NNS who_WP had_VBD raised_VBN concerns_NNS about_IN
        the_DT undue_JJ influence_NN of_IN the_DT pharmaceutical_JJ industry_NN on_IN American_JJ medicine_NN My_PRP$ industry_NN source_NN
        had_VBD information_NN for_IN me_PRP about_IN drug_NN company_NN practices_NNS ,_, but—out_NN of_IN fear_NN of_IN career_NN ruin—would_NN
        only_RB talk_NN on_IN the_DT condition_NN that_IN I_PRP would_MD conceal_VB the_DT scientist_NN 's_POS identity_NN ._.
        For_IN the_DT next_JJ year_NN or_CC so_RB ,_, I_PRP had_VBD repeated_VBN contacts_NNS with_IN the_DT scientist_NN ._. As_IN I_PRP listened_VBD to_TO
        this_DT researcher—and_NN to_TO the_DT other_JJ medical_JJ whistleblowers_NNS that_IN I_PRP continued_VBD to_TO interview—it_NN
        occurred_VBD to_TO me_PRP that_IN each_DT whistleblower_NN was_VBD like_IN the_DT proverbial_JJ blind_JJ man_NN with_IN a_DT hand_NN on_IN the_DT
        elephant_NN ._. Each_DT could_MD describe_VB one_CD piece_NN of_IN the_DT puzzle_NN ,_, but_CC the_DT full_JJ picture_NN could_MD only_RB
        emerge_VB by_IN bringing_VBG these_DT whistleblowers_NNS together_RB ._.
        With_IN an_DT eye_NN to_TO focusing_VBG on_IN the_DT systemic_JJ problems_NNS that_WDT have_VBP allowed_VBN American_JJ medicine_NN to_TO
        be_VB unduly_RB influenced_VBN by_IN industry_NN ,_, on_IN May_NNP 15_CD ,_, 2005_CD ,_, I_PRP brought_VBD together_RB five_CD whistleblowers_NNS
        in_IN Washington_NNP ,_, D_NNP ._. C_NNP ._. I_PRP asked_VBD them_PRP each_DT to_TO tell_VB their_PRP$ story_NN and_CC to_TO suggest_VB ways_NNS to_TO restore_VB
        objectivity_NN to_TO medicine_NN and_CC medical_JJ research_NN ._.
      
      
        The_DT Whistleblowers_NNP
        Four_CD whistleblowers_NNS attended_VBD in_IN person_NN ,_, and_CC the_DT anonymous_JJ industry_NN scientist_NN
        participated_VBD via_IN speakerphone_NN ._. The_DT whistleblowers_NNS came_VBD from_IN an_DT extraordinary_JJ variety_NN of_IN
        different_JJ professional_JJ backgrounds_NNS ._.
        
          
          
            David_NNP Graham_NNP
            This_DT Food_NNP and_CC Drug_NNP Administration_NNP (_( FDA_NNP )_) safety_NN officer_NN raised_VBD concerns_NNS about_IN the_DT
            cardiovascular_JJ side_NN effects_NNS of_IN rofecoxib_NN (_( Vioxx_NNP )_) and_CC other_JJ Cox-_NNP 2_CD inhibitors_NNS ._. He_PRP
            testified_VBD at_IN a_DT United_NNP States_NNPS Senate_NNP Finance_NNP Committee_NNP hearing_NN on_IN rofexocib_NN ,_, the_DT FDA_NNP ,_,
            and_CC Merck_NNP [_NN 1_CD ,_, 2_CD ]_NN ._. Graham_NNP attended_VBD the_DT roundtable_JJ in_IN his_PRP$ own_JJ personal_JJ capacity_NN and_CC was_VBD
            not_RB representing_VBG the_DT FDA_NNP ._.
            
              Each_DT whistleblower_NN was_VBD like_IN the_DT proverbial_JJ blind_JJ man_NN with_IN a_DT hand_NN on_IN the_DT
              elephant_NN ._.
            
          
        
        
          
          
            Allen_NNP Jones_NNP
            This_DT investigator_NN at_IN the_DT Pennsylvania_NNP Office_NNP of_IN the_DT Inspector_NNP General_NNP led_VBD an_DT
            investigation_NN into_IN an_DT off-the-books_JJ account_NN ,_, funded_VBN in_IN part_NN by_IN drug_NN companies_NNS ,_, from_IN
            which_WDT payments_NNS were_VBD made_VBN to_TO state_VB employees_NNS to_TO develop_VB a_DT medication_NN treatment_NN
            algorithm_NN ._. He_PRP filed_VBD a_DT civil_JJ rights_NNS lawsuit_NN against_IN the_DT Pennsylvania_NNP Office_NNP of_IN the_DT
            Inspector_NNP General_NNP to_TO protect_VB his_PRP$ right_NN to_TO publicly_RB discuss_VB his_PRP$ findings_NNS ,_, and_CC was_VBD later_RB
            fired_VBN from_IN his_PRP$ job_NN for_IN talking_VBG to_TO the_DT press_NN [_NN 3_CD –_NN 6_CD ]_NN ._.
          
        
        
          
          
            Stefan_NNP Kruszewski_NNP
            This_DT Harvard-trained_NNP psychiatrist_NN was_VBD hired_VBN by_IN the_DT Bureau_NNP of_IN Program_NNP Integrity_NNP in_IN
            the_DT Pennsylvania_NNP Department_NNP of_IN Public_NNP Welfare_NNP to_TO oversee_VB the_DT state_NN 's_POS mental_JJ health_NN and_CC
            substance_NN misuse_NN programs_NNS ._. He_PRP filed_VBD a_DT law_NN suit_NN in_IN a_DT federal_JJ court_NN in_IN the_DT Middle_NNP
            District_NNP of_IN Pennsylvania_NNP ,_, charging_VBG that_IN he_PRP was_VBD fired_VBN after_IN uncovering_VBG widespread_JJ abuse_NN
            and_CC fraud_NN in_IN the_DT bureau_NN [_NN 7_CD ,_, 8_CD ]_NN ._.
          
        
        
          
          
            Kathleen_NNP Slattery-_NNP Moschkau_NNP
            This_DT former_JJ drug_NN representative_NN left_VBD the_DT pharmaceutical_JJ industry_NN after_IN witnessing_VBG
            marketing_NN practices_NNS that_IN she_PRP found_VBD disturbing_JJ ._. She_PRP wrote_VBD and_CC directed_VBD the_DT movie_NN 
            Side_NNP Effects_NNPS ,_, a_DT fictionalized_JJ account_NN of_IN her_PRP$ experiences_NNS [_NN 9_CD ,_, 10_CD ]_NN ._.
          
        
        
          
          
            The_DT anonymous_JJ research_NN scientist_NN
            This_DT is_VBZ an_DT industry_NN insider_NN who_WP said_VBD to_TO me_PRP ,_, ahead_RB of_IN the_DT roundtable_JJ ,_, that_IN the_DT
            culture_NN of_IN secrecy_NN at_IN drug_NN companies_NNS too_RB often_RB results_VBZ in_IN claims_NNS that_WDT are_VBP closer_JJR to_TO
            “ propaganda_NN” than_IN science_NN ._.
          
        
      
      
        Lessons_NNP Learned_NNP from_IN the_DT Roundtable_NNP
        
          
          
            Ties_NNPS between_IN drug_NN regulators_NNS and_CC industry_NN may_MD influence_VB new_JJ drug_NN approval_NN
            David_NNP Graham_NNP described_VBD the_DT frustrations_NNS he_PRP had_VBD felt_VBN in_IN his_PRP$ almost_RB 20_CD years_NNS of_IN
            experience_NN as_IN an_DT FDA_NNP drug_NN safety_NN officer_NN ._. Although_IN he_PRP was_VBD instrumental_JJ ,_, he_PRP said_VBD ,_, in_IN
            getting_VBG ten_CD drugs_NNS off_IN the_DT market_NN because_IN of_IN safety_NN concerns_NNS ,_, his_PRP$ experience_NN was_VBD like_IN a_DT
            salmon_NN swimming_NN upstream—_NN“ a_DT single_JJ individual_JJ …_NN against_IN the_DT tide_NN ._.” The_DT tide_NN ,_, he_PRP said_VBD ,_, “ is_VBZ
            an_DT entire_JJ institution_NN whose_WP$ mission_NN is_VBZ to_TO approve_VB drugs_NNS and_CC make_VB industry_NN happy_JJ ._.”
            The_DT FDA_NNP ,_, said_VBD Graham_NNP ,_, is_VBZ in_IN a_DT “ collaborative_JJ relationship_NN” with_IN industry_NN ._. The_DT FDA_NNP
            gets_VBZ money_NN from_IN drug_NN companies_NNS through_IN the_DT Prescription_NNP Drug_NNP User_NNP Fee_NN Act_NNP of_IN 1992_CD (_( see_VB
            http_NN :_: /_NN /_NN www_NN ._. fda_NN ._. gov_NN /_NN cber_NN /_NN pdufa_NN ._. htm_NN )_) “ to_TO approve_VB new_JJ drugs_NNS and_CC approve_VB them_PRP more_RBR
            quickly_RB ._.” The_DT mindset_NN at_IN the_DT FDA_NNP ,_, he_PRP said_VBD ,_, is_VBZ that_IN “ we_PRP will_MD find_VB a_DT reason_NN to_TO approve_VB a_DT
            drug_NN no_DT matter_NN how_WRB small_JJ the_DT indication_NN for_IN the_DT drug_NN ._.” Graham_NNP explained_VBD that_IN a_DT senior_JJ
            official_NN at_IN the_DT FDA_NNP had_VBD told_VBN him_PRP :_: “ industry_NN is_VBZ our_PRP$ client_NN ._.“
            When_WRB the_DT FDA_NNP knows_VBZ there_EX is_VBZ a_DT serious_JJ problem_NN with_IN a_DT new_JJ drug_NN ,_, he_PRP said_VBD ,_, the_DT FDA_NNP
            deals_NNS with_IN this_DT by_IN saying_VBG ,_, “ well_RB ,_, we_PRP 'll_MD handle_VB it_PRP in_IN labeling_VBG” even_RB though_RB ,_, said_VBD
            Graham_NNP ,_, “ FDA_NNP knows_VBZ labeling_VBG does_VBZ n't_RB work_VB ._.”
            “ There_EX is_VBZ no_DT independent_JJ voice_NN for_IN drug_NN safety_NN in_IN the_DT United_NNP States_NNPS ,_,” he_PRP said_VBD ._. The_DT
            upper-level_JJ managers_NNS in_IN the_DT FDA_NNP 's_POS Office_NNP of_IN Drug_NNP Safety_NNP are_VBP appointed_VBN from_IN the_DT FDA_NNP 's_POS
            Office_NNP of_IN New_NNP Drugs_NNPS ,_, which_WDT approves_VBZ new_JJ medicines_NNS ._. This_DT makes_VBZ the_DT Office_NNP of_IN Drug_NNP Safety_NNP
            “ captive_NN ,_,” he_PRP said_VBD ,_, to_TO the_DT Office_NNP of_IN New_NNP Drugs_NNPS ._.
            The_DT anonymous_JJ scientist_NN said_VBD that_IN in_IN order_NN to_TO speed_VB up_RP drug_NN approval_NN ,_, companies_NNS
            “ do_VBP n't_RB measure_VB things_NNS like_IN whether_IN we_PRP are_VBP really_RB curing_VBG the_DT disease_NN ,_, or_CC prolonging_VBG
            life_NN ,_, or_CC preventing_VBG hospitalization_NN ,_, or_CC whether_IN a_DT patient_NN is_VBZ truly_RB more_RBR functional_JJ ._.
            Oftentimes_NNP ,_, we_PRP 're_VBP measuring_VBG intermediate_JJ ,_, lesser_JJR things_NNS ,_, markers_NNS ,_, predictors—we_NN 
            hope_VBP —_NN of_IN these_DT clinical_JJ endpoints_NNS ,_, but_CC they_PRP may_MD or_CC may_MD not_RB be_VB
            accurate_JJ ._.”
            And_CC the_DT FDA_NNP ,_, said_VBD the_DT scientist_NN ,_, requires_VBZ just_RB two_CD positive_JJ studies_NNS to_TO grant_VB
            approval_NN to_TO a_DT new_JJ drug_NN ,_, but_CC there_EX is_VBZ no_DT limitation_NN on_IN how_WRB many_JJ negative_JJ studies_NNS can_MD be_VB
            done_VBN before_IN one_CD or_CC two_CD positive_JJ studies_NNS are_VBP produced_VBN ._. This_DT can_MD lead_VB to_TO approval_NN of_IN a_DT
            drug_NN even_RB when_WRB most_JJS studies_NNS are_VBP negative_NN or_CC show_VB no_DT effect_NN ._.
            Both_DT Graham_NNP and_CC the_DT anonymous_JJ scientist_NN suggested_VBD putting_VBG an_DT end_NN to_TO the_DT Prescription_NNP
            Drug_NNP User_NNP Fee_NN Act_NNP ,_, and_CC Graham_NNP argued_VBD that_IN there_EX needs_VBZ to_TO be_VB independent_JJ authority_NN for_IN
            those_DT in_IN charge_NN of_IN drug_NN safety_NN ._. They_PRP indicated_VBD that_IN two_CD bills_NNS in_IN Congress_NNP ,_, introduced_VBN
            by_IN Senator_NNP Grassley_NNP and_CC by_IN Congressman_NNP Hinchey_NNP ,_, at_IN least_JJS partly_RB address_VB these_DT
            concerns_NNS ._.
            “ The_DT pharma–_NN FDA_NNP complex_NN has_VBZ to_TO be_VB dismantled_VBN ,_,” said_VBD Graham_NNP ,_, “ and_CC the_DT American_JJ people_NNS
            have_VBP to_TO insist_VB on_IN that_DT ,_, otherwise_RB we_PRP 're_VBP going_VBG to_TO have_VB disasters_NNS like_IN Vioxx_NNP that_WDT happen_VBP
            in_IN the_DT future_NN ._.”
          
        
        
          
          
            The_DT race_NN to_TO approve_VB new_JJ drugs_NNS without_IN proper_JJ safety_NN testing_NN may_MD be_VB compromising_VBG
            the_DT public_NN 's_POS health_NN
            “ Drug_NN companies_NNS assiduously_RB avoid_VBP acquiring_VBG information_NN about_IN side_NN effects_NNS ,_,” said_VBD
            the_DT industry_NN scientist_NN ._. “ Drug_NN companies_NNS will_MD not_RB conduct_VB safety_NN studies_NNS unless_IN they_PRP
            have_VBP to—meaning_VBG basically_RB that_IN they_PRP 're_VBP required_VBN by_IN a_DT regulator—and_NN that_WDT rarely_RB
            happens_VBZ ._.” High-risk_NNP patients_NNS who_WP might_MD have_VB a_DT bad_JJ reaction_NN to_TO a_DT drug_NN ,_, said_VBD the_DT
            scientist_NN ,_, “ are_VBP excluded_VBN from_IN studies_NNS deliberately_RB ,_, even_RB though_RB ,_, when_WRB the_DT drug_NN is_VBZ
            approved_VBN ,_, these_DT patients_NNS will_MD be_VB targeted_VBN for_IN sales_NNS ._.” When_WRB a_DT safety_NN study_NN is_VBZ proposed_VBN
            within_IN the_DT industry_NN ,_, said_VBD the_DT scientist_NN ,_, “ a_DT typical_JJ response_NN will_MD be_VB that_IN if_IN we_PRP
            conducted_VBD a_DT study_NN to_TO find_VB out_IN if_IN there_EX was_VBD a_DT safety_NN problem_NN ,_, people_NNS would_MD learn_VB about_IN
            it_PRP and_CC think_VBP we_PRP 
            had_VBD a_DT problem_NN [_NN which_WDT ]_NN would_MD destroy_VB the_DT image_NN of_IN safety_NN that_WDT has_VBZ been_VBN
            so_RB carefully_RB constructed_VBN ._.”
            
              “ There_EX is_VBZ no_DT independent_JJ voice_NN for_IN drug_NN safety_NN in_IN the_DT United_NNP States_NNPS ._.”
            
            Studies_NNS are_VBP too_RB small_JJ and_CC are_VBP conducted_VBN over_IN too_RB brief_VB a_DT period_NN to_TO properly_RB assess_VB
            safety_NN :_: “ The_DT largest_JJS studies—the_NN phase_NN three_CD studies_NNS ,_, [_NN which_WDT ]_NN might_MD be_VB several_JJ thousand_CD
            people—last_NN for_IN a_DT few_JJ months_NNS ._. If_IN drugs_NNS kill_VBP one_CD in_IN several_JJ thousand_CD per_IN year_NN ,_, this_DT
            would_MD be_VB a_DT public_JJ health_NN catastrophe_NN ._. A_DT blockbuster_NN drug_NN with_IN that_DT kind_NN of_IN hazard_NN
            associated_VBN with_IN it_PRP could_MD be_VB associated_VBN with_IN tens_NNS of_IN thousands_NNS of_IN deaths_NNS a_DT year_NN ,_, and_CC it_PRP
            would_MD never_RB be_VB detected_VBN in_IN studies_NNS of_IN the_DT kind_NN that_IN we_PRP routinely_RB submit_VBP and_CC are_VBP the_DT
            basis_NN for_IN approval_NN ._.” These_DT drugs_NNS ,_, said_VBD the_DT scientist_NN ,_, and_CC these_DT kinds_NNS of_IN risks_NNS ,_, are_VBP
            “ essentially_RB out_IN there_EX now_RB ,_, unlabeled_JJ ,_, unnoticed_JJ ,_, all_DT beneath_IN the_DT radar_NN ._.”
            The_DT scientist_NN said_VBD that_IN ,_, “ to_TO ensure_VB that_IN safety_NN problems_NNS will_MD go_VB unnoticed_JJ ,_, we_PRP
            compound_NN the_DT problem_NN of_IN conducting_VBG small_JJ studies_NNS by_IN setting_VBG a_DT statistical_JJ threshold_NN for_IN
            acknowledging_VBG the_DT safety_NN problem_NN that_WDT is_VBZ so_RB high_JJ that_IN you_PRP know_VBP in_IN advance_NN it_PRP could_MD
            never_RB be_VB reached_VBN for_IN any_DT serious_JJ side_NN effect_NN ,_, like_IN myocardial_NN infarction_NN ._.” This_DT
            practice_NN ,_, said_VBD the_DT scientist_NN ,_, “ virtually_RB ensures_VBZ that_IN if_IN a_DT bad_JJ side_NN effect_NN happens_VBZ to_TO
            show_VB up_RP ,_, it_PRP 's_VBZ not_RB going_VBG to_TO reach_VB the_DT arbitrary_JJ level_NN that_IN we_PRP call_VBP statistically_RB
            significant_JJ ,_, and_CC the_DT company_NN can_MD maintain_VB that_IN it_PRP 's_VBZ just_RB bad_JJ luck_NN ._.” And_CC if_IN a_DT bad_JJ result_NN
            does_VBZ happen_VB ,_, “ typically_RB a_DT company_NN is_VBZ not_RB going_VBG to_TO publish_VB the_DT study_NN at_IN all_DT ._. If_IN they_PRP do_VBP
            publish_VB it_PRP ,_, the_DT bad_JJ result_NN can_MD be_VB omitted_VBN as_RB ‘ not_RB statistically_RB important_JJ ._.’”
          
        
        
          
          
            The_DT funding_NN of_IN state_NN officials_NNS by_IN industry_NN may_MD be_VB affecting_VBG prescribing_VBG
            patterns_NNS
            Allen_NNP Jones_NNP described_VBD how_WRB he_PRP believed_VBD that_IN drug_NN companies_NNS were_VBD acting_VBG at_IN the_DT state_NN
            level_NN to_TO influence_VB the_DT prescribing_VBG of_IN psychiatric_JJ medications_NNS ._.
            “ I_PRP began_VBD to_TO investigate_VB an_DT account_NN into_IN which_WDT pharmaceutical_JJ companies_NNS were_VBD paying_VBG
            money_NN that_WDT was_VBD being_VBG accessed_JJ by_IN state_NN employees_NNS ,_,” he_PRP said_VBD ._. “ Additionally_RB ,_, I_PRP found_VBD that_IN
            various_JJ pharmaceutical_JJ companies_NNS were_VBD paying_VBG state_NN employees_NNS directly—also_NN giving_VBG them_PRP
            trips_NNS ,_, perks_NNS ,_, lavish_JJ meals_NNS ,_, transportation_NN ,_, honorariums_NNS up_IN to_TO $_$ 2_CD ,_, 000_CD for_IN speaking_VBG in_IN
            their_PRP$ official_JJ capacities_NNS at_IN drug_NN company_NN events_NNS ._. They_PRP were_VBD given_VBN unrestricted_JJ
            educational_JJ grants_NNS that_WDT were_VBD deposited_VBN into_IN an_DT off-the-books_JJ account—unregistered_JJ ,_,
            unmonitored_JJ ,_, literally_RB operated_VBN out_IN of_IN a_DT drawer_NN ._.”
            These_DT same_JJ state_NN officials_NNS ,_, he_PRP said_VBD ,_, were_VBD responsible_JJ for_IN dictating_NN clinical_JJ policy_NN
            and_CC writing_VBG guidelines_NNS for_IN the_DT treatment_NN of_IN patients_NNS in_IN the_DT state_NN system_NN ._. These_DT
            officials_NNS were_VBD ,_, he_PRP said_VBD ,_, receiving_VBG money_NN from_IN companies_NNS with_IN a_DT stake_NN in_IN the_DT guidelines_NNS ._.
            “ The_DT protocol_NN they_PRP [_NN the_DT officials_NNS ]_NN were_VBD developing_VBG was_VBD called_VBN the_DT Texas_NNP Medication_NNP
            Algorithm_NNP Project_NNP ,_, TMAP_NNP ,_, which_WDT began_VBD in_IN Texas_NNP in_IN the_DT mid-_NN 90_CD s_VBZ ._. It_PRP outlined_VBD detailed_JJ
            medication_NN guidelines_NNS for_IN schizophrenia_NN ,_, depression_NN ,_, and_CC bipolar_NN disorder_NN ._. It_PRP
            recommends_VBZ almost_RB exclusive_JJ usage_NN of_IN newer_JJR ,_, patented_VBD ,_, very_RB expensive_JJ atypical_JJ
            antipsychotics_NNS ,_, SSRIs_NNP [_NN selective_JJ serotonin_NN uptake_NN inhibitors_NNS ]_NN ,_, and_CC mood_NN stabilizers_NNS ._.”
            The_DT Texas_NNP Medication_NNP Algorithm_NNP Project_NNP ,_, said_VBD Jones_NNP ,_, was_VBD based_VBN on_IN “ expert_NN consensus_NN”
            from_IN industry-supported_JJ meetings_NNS ._.
            Jones_NNP said_VBD that_IN when_WRB he_PRP wanted_VBD to_TO investigate_VB these_DT findings_NNS ,_, he_PRP was_VBD shut_VBN down_RB ._. “ I_PRP
            was_VBD told_VBN point_NN black_JJ ,_, ‘ Look_VB ,_, drug_NN companies_NNS write_VBP checks_NNS to_TO politicians_NNS ,_, they_PRP write_VBP
            checks_NNS to_TO politicians_NNS on_IN both_DT sides_NNS of_IN the_DT aisle—back_NN off_RP ._.’” He_PRP was_VBD told_VBN ,_, he_PRP said_VBD ,_, to_TO
            “ quit_VB being_VBG a_DT salmon_NN ,_, quit_VBD swimming_VBG against_IN a_DT stream_NN ._.” He_PRP would_MD n't_RB back_RB down_RB from_IN his_PRP$
            investigation_NN ,_, he_PRP said_VBD ,_, and_CC was_VBD demoted_VBN ._. On_IN November_NNP 22_CD ,_, 2002_CD ,_, he_PRP filed_VBD a_DT civil_JJ rights_NNS
            lawsuit_NN “ to_TO preserve_VB my_PRP$ job_NN and_CC my_PRP$ right_NN to_TO speak_VB out_RP ._.” His_PRP$ employer_NN ,_, he_PRP said_VBD ,_, took_VBD him_PRP
            off_IN investigative_JJ duties_NNS altogether_RB ._.
            Stefan_NNP Kruszewski_NNP ,_, who_WP has_VBZ filed_VBN a_DT law_NN suit_NN in_IN a_DT federal_JJ court_NN in_IN Pennsylvania_NNP ,_,
            raised_VBD concerns_NNS to_TO his_PRP$ seniors_NNS in_IN the_DT Pennsylvania_NNP Department_NNP of_IN Public_NNP Welfare_NNP about_IN
            prescribing_VBG practices_NNS in_IN the_DT state_NN that_IN he_PRP did_VBD not_RB feel_VB were_VBD evidence_NN based_VBD ,_, and_CC said_VBD
            he_PRP lost_VBD his_PRP$ job_NN for_IN raising_VBG his_PRP$ concerns_NNS ._. For_IN example_NN ,_, he_PRP alerted_VBD his_PRP$ seniors_NNS to_TO the_DT
            off-label_JJ prescribing_VBG of_IN the_DT anticonvulsant_NN gabapentin_NN (_( Neurontin_NNP )_) for_IN mood_NN disorders_NNS
            and_CC addictive_JJ disorders_NNS ._.
            “ The_DT pharmaceutical_JJ industry_NN is_VBZ the_DT single_JJ most_RBS powerful_JJ lobbying_NN group_NN on_IN Capitol_NNP
            Hill—outspending_NNP even_RB the_DT oil_NN and_CC banking_NN industries_NNS ,_,” said_VBD Jones_NNP ._. “ It_PRP should_MD come_VB as_IN
            no_DT surprise_NN that_IN the_DT ties_NNS go_VBP far_RB beyond_IN just_RB the_DT mental_JJ health_NN officials_NNS who_WP wrote_VBD the_DT
            guidelines_NNS ,_, but_CC extend_VB to_TO many_JJ of_IN the_DT politicians_NNS who_WP ,_, in_IN the_DT end_NN ,_, allowed_VBD an_DT
            investigation_NN into_IN pharma_NN corruption_NN to_TO be_VB dropped_VBN ,_, and_CC the_DT investigator—me—to_NN be_VB
            fired_VBN ._.”
            Efforts_NNS to_TO detect_VB and_CC deter_VB fraud_NN and_CC abuse_VB due_JJ to_TO these_DT conflicts_NNS ,_, he_PRP said_VBD ,_, “ will_MD
            be_VB likely_JJ to_TO be_VB undermined_VBN as_RB long_RB as_IN those_DT charged_VBN with_IN detecting_VBG fraud_NN and_CC abuse_NN ,_,
            like_IN the_DT [_NN Pennsylvania_NNP ]_NN Inspector_NNP General_NNP ,_, are_VBP appointed_VBN by_IN politicians_NNS who_WP are_VBP
            themselves_PRP beholden_JJ to_TO the_DT drug_NN industry_NN ._. Such_JJ positions_NNS should_MD instead_RB be_VB filled_VBN by_IN
            career_NN civil_JJ servants_NNS and_CC not_RB political_JJ appointees_NNS ._.”
          
        
        
          
          
            Regulatory_NNP agencies_NNS are_VBP not_RB being_VBG held_VBN accountable_JJ
            In_IN comments_NNS that_WDT echoed_VBD his_PRP$ testimony_NN to_TO the_DT US_NNP Senate_NNP Finance_NNP Committee_NNP ,_, Graham_NNP
            said_VBD that_IN ,_, “ FDA_NNP was_VBD the_DT single_JJ greatest_JJS obstacle_NN to_TO doing_VBG anything_NN effective_JJ with_IN
            Vioxx_NNP ._. As_IN a_DT result_NN ,_, nearly_RB 60_CD ,_, 000_CD people_NNS probably_RB died_VBD from_IN that_DT drug_NN ._. That_DT 's_VBZ as_IN many_JJ
            of_IN our_PRP$ soldiers_NNS that_WDT were_VBD killed_VBN in_IN the_DT Vietnam_NNP war_NN [_NN who_WP ]_NN died_VBD as_IN a_DT result_NN of_IN Vioxx_NNP
            use_NN ._. And_CC FDA_NNP had_VBD the_DT opportunity_NN ,_, the_DT responsibility_NN ,_, to_TO stop_VB that_IN and_CC did_VBD n't_RB ._. In_IN fact_NN ,_,
            FDA_NNP allowed_VBD it_PRP to_TO continue_VB ._. In_IN my_PRP$ book_NN ,_, FDA_NNP shares_NNS in_IN the_DT responsibility_NN for_IN those_DT
            deaths_NNS and_CC yet_RB it_PRP 's_VBZ not_RB being_VBG held_VBN accountable_JJ by_IN Congress_NNP ._.” Congress_NNP itself_PRP ,_, added_VBD
            Graham_NNP ,_, is_VBZ deeply_RB beholden_JJ to_TO the_DT drug_NN industry_NN since_IN many_JJ politicians_NNS receive_VBP “ often_RB
            quite_RB a_DT bit_NN of_IN campaign_NN contributions_NNS” from_IN the_DT industry_NN ._.
            Kruszewski_NNP reflected_VBD upon_IN the_DT problems_NNS he_PRP said_VBD he_PRP had_VBD encountered_VBN in_IN Pennsylvania_NNP ,_,
            saying_VBG that_IN “ there_EX is_VBZ no_DT accountability_NN in_IN the_DT system_NN for_IN oversight_NN [_NN agencies_NNS ]_NN ._.” He_PRP has_VBZ
            become_VBN “ a_DT stronger_JJR advocate_NN than_IN ever_RB for_IN a_DT federal_JJ patient_NN bill_NN of_IN rights_NNS ._.”
          
        
        
          
          
            Marketing_NN departments_NNS can_MD influence_VB doctors_NNS’ prescribing_VBG habits_NNS
            The_DT research_NN scientist_NN said_VBD that_IN the_DT job_NN was_VBD attractive_JJ because_IN of_IN the_DT “ many_JJ
            excellent_JJ drugs_NNS” developed_VBN ,_, such_JJ as_IN drugs_NNS to_TO treat_VB HIV_NNP ,_, but_CC the_DT scientist_NN “ also_RB saw_VBD
            drugs_NNS marketed_VBN in_IN a_DT way_NN that_WDT will_MD exaggerate_VB the_DT benefits_NNS and_CC conceal_VB the_DT risks_NNS ._.”
            Kathleen_NNP Slattery-_NNP Moschkau_NNP gave_VBD an_DT insider_NN 's_POS view_NN of_IN drug_NN marketing_NN practices_NNS ,_, from_IN
            her_PRP$ former_JJ experiences_NNS as_IN a_DT drug_NN rep_NN ._. She_PRP clutched_JJ her_PRP$ head_NN in_IN disbelief_NN as_IN she_PRP told_VBD
            the_DT roundtable_JJ that_IN doctors_NNS would_MD come_VB up_IN to_TO her_PRP with_IN patients_NNS '_POS charts_NNS asking_VBG her_PRP for_IN
            advice_NN on_IN treating_VBG patients_NNS ._. Slattery-_NNP Moschkau_NNP ,_, like_IN most_JJS of_IN the_DT drug_NN representatives_NNS
            she_PRP came_VBD to_TO know_VB over_IN the_DT years_NNS ,_, had_VBD no_DT science_NN background_NN at_IN all_DT ._.
            
              “ Drug_NN companies_NNS assiduously_RB avoid_VBP acquiring_VBG information_NN about_IN side_NN effects_NNS ._.”
            
            The_DT various_JJ techniques_NNS drug_NN representatives_NNS were_VBD trained_VBN in_IN to_TO “ educate_VB doctors_NNS”
            eventually_RB proved_VBD to_TO be_VB not_RB just_RB “ comical_JJ” but_CC “ also_RB scary_JJ ,_,” she_PRP said_VBD ._. “ Whether_IN it_PRP was_VBD
            hiring_VBG ,_, training_NN ,_, what_WP we_PRP were_VBD told_VBN to_TO say_VB about_IN drugs_NNS and_CC what_WP we_PRP were_VBD told_VBN not_RB to_TO
            say_VB ,_,” it_PRP was_VBD marketing_VBG ,_, not_RB science_NN ,_, that_DT dominated_VBD ._. One_CD of_IN the_DT techniques_NNS used_VBN by_IN drug_NN
            companies_NNS was_VBD to_TO buy_VB doctors_NNS '_POS prescribing_VBG records_NNS so_RB drug_NN representatives_NNS knew_VBD “ to_TO the_DT
            dime_NN” what_WP drugs_NNS doctors_NNS were_VBD prescribing_VBG and_CC could_MD tailor_NN their_PRP$ marketing_NN to_TO them_PRP ._.
            Drug_NN representatives_NNS developed_VBD “ personality_NN profiles_NNS” on_IN doctors_NNS and_CC were_VBD taught_VBN to_TO
            pitch_VB their_PRP$ sales_NNS to_TO specific_JJ personality_NN types_NNS ._. Representatives_NNS were_VBD compensated_VBN ,_, she_PRP
            said_VBD ,_, by_IN “ how_WRB many_JJ prescriptions_NNS we_PRP could_MD encourage_VB ._.”
            Both_DT Slattery-_NNP Moschkau_NNP and_CC the_DT industry_NN scientist_NN described_VBD tensions_NNS within_IN drug_NN
            companies_NNS between_IN marketing_NN departments_NNS and_CC industry_NN scientists_NNS ._. “ The_DT marketing_NN spin_NN on_IN
            things_NNS ,_,” said_VBD the_DT scientist_NN ,_, “ carries_VBZ the_DT day_NN ._.”
          
        
        
          
          
            The_DT published_VBN medical_JJ literature_NN contains_VBZ many_JJ biases_NNS
            “ When_WRB studies_NNS are_VBP published_VBN ,_,” said_VBD the_DT scientist_NN ,_, “ they_PRP are_VBP frequently_RB written_VBN not_RB
            by_IN the_DT trained_VBN research_NN scientist_NN ,_, who_WP might_MD have_VB designed_VBN and_CC analyzed_VBN the_DT study_NN ,_, but_CC
            by_IN a_DT designated_VBN medical_JJ writer_NN with_IN little_JJ if_IN any_DT background_NN in_IN research_NN ,_, but_CC who_WP is_VBZ
            trained_VBN instead_RB to_TO craft_VB the_DT findings_NNS of_IN the_DT study_NN in_IN the_DT best_JJS possible_JJ way_NN for_IN the_DT
            company_NN ._.”
            The_DT body_NN of_IN literature_NN available_JJ to_TO the_DT public_NN ,_, said_VBD the_DT scientist_NN ,_, “ is_VBZ a_DT biased_VBN
            sample_NN of_IN what_WP companies_NNS want_VBP people_NNS to_TO see_VB ._.” The_DT research_NN scientist_NN described_VBD “ a_DT
            culture_NN of_IN secrecy_NN ,_,” which_WDT makes_VBZ it_PRP hard_JJ even_RB for_IN industry_NN scientists_NNS tasked_JJ with_IN
            ensuring_VBG drug_NN safety_NN to_TO obtain_VB the_DT full_JJ datasets_NNS needed_VBN to_TO genuinely_RB understand_VB a_DT
            drug_NN 's_POS risk–benefit_NN profile_NN ._.
          
        
      
      
        Conclusion_NNP
        Whistleblowers_NNP have_VBP been_VBN compared_VBN to_TO bees—they_NN have_VBP just_RB one_CD sting_NN to_TO use_VB and_CC using_VBG it_PRP
        may_MD lead_VB to_TO career_NN suicide_NN [_NN 11_CD ]_NN ._. Many_JJ of_IN the_DT whistleblowers_NNS at_IN the_DT roundtable_JJ said_VBD they_PRP had_VBD
        experienced_VBN retaliation_NN from_IN their_PRP$ employers_NNS for_IN raising_VBG concerns_NNS ,_, but_CC all_DT had_VBD felt_VBN
        obligated_VBN to_TO speak_VB out_IN about_IN practices_NNS in_IN medicine_NN and_CC medical_JJ research_NN that_IN they_PRP believe_VBP
        are_VBP risking_VBG the_DT public_NN 's_POS health_NN or_CC safety_NN ._. Graham_NNP said_VBD he_PRP felt_VBD “ trapped_VBN by_IN the_DT truth_NN” and_CC
        had_VBD to_TO act_VB ._. “ There_EX are_VBP bigger_JJR issues_NNS here_RB ,_,” said_VBD Kruszewski_NNP ._. “ I_PRP felt_VBD right_NN from_IN the_DT start_NN
        [_NN that_DT ]_NN if_IN I_PRP wallowed_JJ in_IN self-pity_JJ about_IN being_VBG fired_VBN and_CC having_VBG my_PRP$ belongings_NNS piled_VBD in_IN the_DT
        gutter_NN that_IN I_PRP would_MD never_RB understand_VB why_WRB all_PDT these_DT things_NNS were_VBD happening_VBG ._. The_DT bigger_JJR issue_NN
        is_VBZ that_IN we_PRP 've_VBP got_VBN people_NNS in_IN the_DT pharmaceutical_JJ industry_NN and_CC the_DT health-care_NN industry_NN all_DT
        acting_VBG in_IN synchrony_NN ._.”
        Each_DT of_IN these_DT whistleblowers_NNS ,_, in_IN very_RB different_JJ ways—from_NN making_VBG a_DT satiric_JJ film_NN to_TO
        speaking_VBG out_IN in_IN Congress—has_NNP shone_NN light_JJ on_IN how_WRB this_DT “ synchrony_NN” may_MD be_VB compromising_VBG the_DT
        integrity_NN of_IN American_JJ medicine_NN ._. We_PRP should_MD not_RB have_VB to_TO rely_VB on_IN medical_JJ whistleblowers_NNS to_TO
        alert_VB us_PRP to_TO these_DT fault_NN lines_NNS ._. If_IN we_PRP are_VBP to_TO restore_VB objectivity_NN to_TO drug_NN development_NN ,_,
        prescribing_VBG ,_, and_CC safety_NN monitoring_NN ,_, we_PRP must_MD be_VB willing_JJ to_TO examine_VB and_CC change_VB all_DT of_IN the_DT
        institutions_NNS that_WDT allow_VBP this_DT synchrony_NN to_TO occur_VB ._.
      
    
  
